Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Maravai Lifesciences Holdings Inc Cl A (MRVI)

Maravai Lifesciences Holdings Inc Cl A (MRVI)
4.03 x 5 4.40 x 1
Post-market by (Cboe BZX)
4.11 +0.16 (+4.05%) 02/21/25 [NASDAQ]
4.03 x 5 4.40 x 1
Post-market 4.15 +0.04 (+0.97%) 17:52 ET
Quote Overview for Fri, Feb 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
3.93
Day High
4.30
Open 4.05
Previous Close 3.95 3.95
Volume 5,467,353 5,467,353
Avg Vol 2,354,177 2,354,177
Stochastic %K 6.52% 6.52%
Weighted Alpha -52.59 -52.59
5-Day Change -0.01 (-0.24%) -0.01 (-0.24%)
52-Week Range 3.93 - 11.56 3.93 - 11.56
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 997,486
  • Shares Outstanding, K 252,528
  • Annual Sales, $ 288,950 K
  • Annual Income, $ -119,030 K
  • EBIT $ -44 M
  • EBITDA $ 8 M
  • 60-Month Beta -0.08
  • Price/Sales 1.93
  • Price/Cash Flow 43.08
  • Price/Book 1.68

Options Overview Details

View History
  • Implied Volatility 164.15% ( -1.19%)
  • Historical Volatility 90.35%
  • IV Percentile 98%
  • IV Rank 76.14%
  • IV High 208.69% on 02/06/25
  • IV Low 22.00% on 05/31/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2,191
  • Volume Avg (30-Day) 465
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 11,053
  • Open Int (30-Day) 10,022

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.06
  • Number of Estimates 5
  • High Estimate -0.05
  • Low Estimate -0.07
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.93 +4.58%
on 02/21/25
Period Open: 5.23
6.05 -32.07%
on 01/28/25
-1.12 (-21.41%)
since 01/21/25
3-Month
3.93 +4.58%
on 02/21/25
Period Open: 4.96
6.21 -33.82%
on 01/08/25
-0.85 (-17.14%)
since 11/21/24
52-Week
3.93 +4.58%
on 02/21/25
Period Open: 5.26
11.56 -64.43%
on 05/17/24
-1.15 (-21.86%)
since 02/21/24

Most Recent Stories

More News
Maravai LifeSciences Announces Preliminary Unaudited 2024 Revenue

MRVI : 4.11 (+4.05%)
Maravai LifeSciences Appoints R. Andrew Eckert as New Chairman of the Board Following Carl Hull's Retirement

Maravai LifeSciences announces Carl Hull's retirement as Executive Chairman, appointing R. Andrew Eckert as his successor.Quiver AI SummaryMaravai LifeSciences Holdings, Inc. announced the retirement of...

MRVI : 4.11 (+4.05%)
Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors

MRVI : 4.11 (+4.05%)
Maravai LifeSciences Announces November 2024 Investor Conference Schedule

MRVI : 4.11 (+4.05%)
Maravai LifeSciences (MRVI) Q3 2024 Earnings Call Transcript

MRVI earnings call for the period ending September 30, 2024.

MRVI : 4.11 (+4.05%)
Maravai LifeSciences Reports Third Quarter 2024 Financial Results

MRVI : 4.11 (+4.05%)
Maravai LifeSciences To Host Earnings Conference Call on Thursday, November 7, 2024

MRVI : 4.11 (+4.05%)
Maravai LifeSciences (MRVI) Q2 2024 Earnings Call Transcript

MRVI earnings call for the period ending June 30, 2024.

MRVI : 4.11 (+4.05%)
Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics

- Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT Platform Profitability -- Applied DNA Secures Commercial Linea RNAP Quantity Sufficient...

APDN : 0.1570 (-2.91%)
MRVI : 4.11 (+4.05%)
Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics

- Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT Platform Profitability -- Applied DNA Secures Commercial Linea RNAP Quantity Sufficient...

APDN : 0.1570 (-2.91%)
MRVI : 4.11 (+4.05%)
Maravai LifeSciences (MRVI) Q1 2024 Earnings Call Transcript

MRVI earnings call for the period ending March 31, 2024.

MRVI : 4.11 (+4.05%)
Maravai LifeSciences (MRVI) Q4 2023 Earnings Call Transcript

MRVI earnings call for the period ending December 31, 2023.

MRVI : 4.11 (+4.05%)
Maravai LifeSciences (MRVI) Q3 2023 Earnings Call Transcript

MRVI earnings call for the period ending September 30, 2023.

MRVI : 4.11 (+4.05%)
Stock Index Futures Plunge as China Trade Data Disappoints, Moody's Downgrades U.S. Banks

September S&P 500 futures (ESU23) are down -0.45%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.49% this morning as fresh worries about China’s economic rebound and the state of U.S. banks...

ESU23 : 4,491.72s (-0.32%)
NQU23 : 15,435.20s (-0.28%)
BRK.A : 718,750.00 (-0.59%)
SOVO : 22.98 (+0.13%)
TSN : 60.45 (+2.27%)
TSLA : 337.80 (-4.68%)
LLY : 873.68 (+0.06%)
UPS : 116.33 (-0.23%)
ZTS : 160.46 (+1.93%)
DUK : 115.55 (+2.11%)
GLEN.LN : 323.850 (-0.52%)
CHGG : 1.4300 (-2.72%)
Maravai LifeSciences (MRVI) Q2 2023 Earnings Call Transcript

MRVI earnings call for the period ending June 30, 2023.

MRVI : 4.11 (+4.05%)
Maravai LifeSciences (MRVI) Q1 2023 Earnings Call Transcript

MRVI earnings call for the period ending March 31, 2023.

MRVI : 4.11 (+4.05%)
2 Top Biotech Stocks to Buy In March and Hold Forever

Their price is right, and their future is bright.

MRNA : 35.53 (+5.34%)
MRVI : 4.11 (+4.05%)
Don't Miss Out on These 2 Undervalued Stocks With Huge Growth Potential

There isn't much that's stopping them from penetrating their markets globally.

INMD : 18.90 (-0.37%)
MRVI : 4.11 (+4.05%)
Maravai LifeSciences (MRVI) Q4 2022 Earnings Call Transcript

MRVI earnings call for the period ending December 31, 2022.

MRVI : 4.11 (+4.05%)
2 Healthcare Companies That Could Be Acquired Within 5 Years

These stocks are also cheap buys that are down more than 60% from their highs.

PFE : 26.30 (+1.54%)
MRVI : 4.11 (+4.05%)
GDRX : 4.81 (-1.03%)
3 Great Growth Stocks Down 20% or More to Buy Now

Buy on the dip. You've no doubt heard the expression plenty of times in the past. Granted, some stocks aren't good candidates to buy when they've pulled back. However, you can also often make a lot of...

BEAM : 30.43 (-8.18%)
MRVI : 4.11 (+4.05%)
NVAX : 7.99 (+0.88%)
3 Biopharma Stocks That Could Help Make You a Fortune

All three are protected by sales of in-demand products, with more on the way.

VRTX : 484.24 (+0.81%)
MRNA : 35.53 (+5.34%)
MRVI : 4.11 (+4.05%)
2 Biotech Stocks You Can Buy and Hold for the Next Decade

These two companies are facing short-term issues that are likely to give way to long-term success.

BNTX : 120.01 (+1.81%)
MRK : 89.50 (+2.08%)
PFE : 26.30 (+1.54%)
MRVI : 4.11 (+4.05%)
DNA : 10.82 (-5.34%)
Maravai LifeSciences Holdings, Inc. (MRVI) Q3 2022 Earnings Call Transcript

MRVI earnings call for the period ending September 30, 2022.

MRVI : 4.11 (+4.05%)
This Fallen Growth Stock Is Still a Wall Street Favorite: Here's Why

It's positioned to benefit from the emergence of a new, long-term trend in biopharma.

PFE : 26.30 (+1.54%)
MRVI : 4.11 (+4.05%)
Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2022 Earnings Call Transcript

MRVI earnings call for the period ending June 30, 2022.

MRVI : 4.11 (+4.05%)
3 of the Best Bear Market Buys for August

Buying all three of these stocks would give you some great diversification in toys, tech, and healthcare.

PFE : 26.30 (+1.54%)
MRVI : 4.11 (+4.05%)
META : 683.55 (-1.62%)
MAT : 21.15 (-2.98%)
CORRECTION: Maravai Lifesciences Reports Second Quarter 2022 Financial Results

SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today, August 4th, by Maravai LifeSciences Holdings,...

MRVI : 4.11 (+4.05%)
Maravai Lifesciences Reports Second Quarter 2022 Financial Results

Record First Half Revenue, EBITDA, Adjusted EBITDA and EPS...

MRVI : 4.11 (+4.05%)
3 Beaten-Down Stocks That Could Soar in the Second Half of 2022

Each of these stocks is ready for a rebound.

AXSM : 137.75 (+6.70%)
MRVI : 4.11 (+4.05%)
NVCR : 22.09 (+2.03%)

Business Summary

Maravai LifeSciences Holdings Inc. is a life sciences company providing products for the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The company offer products and services in the fields of nucleic acid synthesis, bioprocess impurity detection and...

See More

Key Turning Points

3rd Resistance Point 4.67
2nd Resistance Point 4.48
1st Resistance Point 4.30
Last Price 4.11
1st Support Level 3.93
2nd Support Level 3.74
3rd Support Level 3.56

See More

52-Week High 11.56
Fibonacci 61.8% 8.64
Fibonacci 50% 7.74
Fibonacci 38.2% 6.84
Last Price 4.11
52-Week Low 3.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements